In vitro characterization of five humanized OKT3 effector function variant antibodies

被引:181
作者
Xu, DL [1 ]
Alegre, ML
Varga, SS
Rothermel, AL
Collins, AM
Pulito, VL
Hanna, LS
Dolan, KP
Parren, PWHI
Bluestone, JA
Jolliffe, LK
Zivin, RA
机构
[1] RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA
[2] Univ Chicago, Ben May Inst, Comm Immunol, Chicago, IL 60637 USA
[3] Yale Univ, New Haven, CT 06511 USA
[4] Alex Pharmaceut Inc, New Haven, CT 06511 USA
[5] Cell & Mol Technol Inc, Phillipsburg, NJ 08865 USA
[6] Scripps Res Inst, Res Inst, La Jolla, CA 92037 USA
关键词
D O I
10.1006/cimm.2000.1617
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Orthoclone OKT 3 (mOKT3) is a highly effective agent for the reversal of steroid-resistant renal allograft rejection. However, its wider use has been limited by the development of a human anti-mouse antibody response (HAMA) and by the "cytokine release syndrome" (CRS). CRS has been associated with T cell/monocyte activation and, secondarily, with activation of the complement cascade. These processes are mediated through Abs' Fc regions by their abilities to cross-link T cells and mononuclear cells and to activate complements. To alleviate these problems, a group of five huIgG1- and huIgG4-based OKT3 wildtype antibodies and their corresponding Fc mutants with altered residues at amino acids 234, 235, and 318, reported to be required for Fc gamma RI and Fc gamma RII binding and complement fixation, were constructed. Characterization of these humanized OKT3 Abs, denoted huOKT3 gamma 1, huOKT3 gamma 4, huOKT3 gamma 1(A(234), A(235)), huOKT3 gamma 4(A(234), A(235)) and huOKT3 gamma 1(A(318)), has demonstrated that huOKT3 gamma 1(A(234), A(235)) and huOKT3y4(A(234), A(235)) and have at least a 100-fold reduced binding to Fc gamma RI and Fc gamma RII. As expected, they are much less potent in the induction of T cell activation and cytokine release, yet retain in vitro immunosuppressive effects as potent as those of mOKT3. Unexpectedly, while huORT3 gamma 1(A(318)) did not show any reduction in its ability to bind C1q and to fix a complement huOKT3 gamma 1(A(234), A(235)) was completely inactive. The in vitro characteristics of huOKT3 gamma 1(A(234), A(235)) are consistent with recent in vivo studies, in which this Ab showed greatly reduced HABU and CRS with the retention of its ability to reverse ongoing graft rejection in man. (C) 2000 Academic Press.
引用
收藏
页码:16 / 26
页数:11
相关论文
共 49 条
[1]   RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL-ANTIBODY IN KIDNEY-TRANSPLANT RECIPIENTS [J].
ABRAMOWICZ, D ;
SCHANDENE, L ;
GOLDMAN, M ;
CRUSIAUX, A ;
VEREERSTRAETEN, P ;
DEPAUW, L ;
WYBRAN, J ;
KINNAERT, P ;
DUPONT, E ;
TOUSSAINT, C .
TRANSPLANTATION, 1989, 47 (04) :606-608
[2]   OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival [J].
Abramowicz, D ;
Norman, DJ ;
Vereerstraeten, P ;
Goldman, M ;
DePauw, L ;
Vanherweghem, JL ;
Kinnaert, P ;
Kahana, L ;
Stuart, FP ;
Thistlethwaite, JR ;
Shield, CF ;
Monaco, A ;
Wu, SC ;
Haverty, TP .
KIDNEY INTERNATIONAL, 1996, 49 (03) :768-772
[3]  
ACKERMANN JR, 1988, TRANSPLANT P, V20, P242
[4]  
Adair John R., 1994, Human Antibodies and Hybridomas, V5, P41
[5]  
ALEGRE ML, 1992, J IMMUNOL, V148, P3461
[6]  
ALEGRE ML, 1994, TRANSPLANTATION, V57, P1537
[7]   COMPARISON OF THE EFFECTOR FUNCTIONS OF HUMAN-IMMUNOGLOBULINS USING A MATCHED SET OF CHIMERIC ANTIBODIES [J].
BRUGGEMANN, M ;
WILLIAMS, GT ;
BINDON, CI ;
CLARK, MR ;
WALKER, MR ;
JEFFERIS, R ;
WALDMANN, H ;
NEUBERGER, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) :1351-1361
[8]   THE C1Q RECEPTOR-SITE ON IMMUNOGLOBULIN-G [J].
BURTON, DR ;
BOYD, J ;
BRAMPTON, AD ;
EASTERBROOKSMITH, SB ;
EMANUEL, EJ ;
NOVOTNY, J ;
RADEMACHER, TW ;
VANSCHRAVENDIJK, MR ;
STERNBERG, MJE ;
DWEK, RA .
NATURE, 1980, 288 (5789) :338-344
[9]   THE BINDING-AFFINITY OF HUMAN-IGG FOR ITS HIGH-AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO-ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION [J].
CANFIELD, SM ;
MORRISON, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (06) :1483-1491
[10]  
CEUPPENS JL, 1985, J IMMUNOL, V135, P3882